On September 9, 2021 Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, reported the appointment of Frank J. Hsu, M.D., as Chief Medical Officer, effective immediately (Press release, Apexigen, SEP 9, 2021, View Source [SID1234590985]). An accomplished industry veteran, Dr. Hsu will lead the ongoing clinical development of Apexigen’s lead investigational immuno-oncology drug, sotigalimab, an anti-CD40 antibody. He will also oversee clinical and regulatory strategy and execution for Apexigen’s expanding pipeline of immuno-oncology therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to welcome Frank to Apexigen," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "He brings comprehensive drug development and regulatory expertise, proven leadership abilities and a fierce drive to improve patient outcomes. Frank has been on the forefront of innovation in immuno-oncology and has successfully brought multiple drugs to patients. We are confident that Frank will help drive the full potential of sotigalimab, which we believe may offer an important breakthrough in this field, as well as our broader pipeline."

Dr. Hsu added, "I am excited to join Apexigen, whose emerging data suggest sotigalimab — a potentially first-in-class and best-in-class CD40 agonist — may provide superior clinical benefit in several critically important cancer indications. I look forward to working with Apexigen’s outstanding team as we drive sotigalimab through its broad Phase 2 program and into registrational trials. Apexigen’s technology has created an innovative pipeline of next-generation, high quality antibody therapeutics and I am excited to be part of bringing these novel agents into the clinic."

Dr. Hsu has extensive experience in cancer drug development in biotech and academia and has advanced multiple biologics from early preclinical development through first-in-human studies and late-stage clinical development. Most recently, he served as Chief Medical Officer at Oncternal Therapeutics and before that he served as Vice President and Head of Oncology at Immune Design Corporation, where he was responsible for development of several immuno-oncology programs, prior to its acquisition by Merck. Previously, Dr. Hsu served as Chief Medical Officer at Zyngenia, where he was responsible for development of its multivalent protein therapeutics, and as Senior Medical Director at Genzyme. Dr. Hsu was a faculty member at Yale University, serving as an Assistant Professor of Medicine in the Section of Oncology and Co-Director/Director of the Immunology Research Program of the Yale Cancer Center. He began his academic career as a Clinical and Research Fellow in oncology at Stanford.

Dr. Hsu holds a B.S. degree in biology from Stanford University, and an M.D. degree from Harvard Medical School and the Health Science and Technology Program at the Massachusetts Institute of Technology. He completed his internship/residency in Internal Medicine at the University of California, San Francisco and his oncology training at Stanford University.

On September 9, 2021 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, reported that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, AnaptysBio, SEP 9, 2021, View Source [SID1234590737]). The presentation will be available on Monday September 13, 2021, at 7:00 a.m. ET via: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will also be available through the investor section of the AnaptysBio website at View Source A replay of the webcast will be available for 90 days following the event.

On September 9, 2021 Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, reported that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer (Press release, Flamingo Therapeutics, SEP 9, 2021, View Source [SID1234587583]). This alliance is an expansion of an existing collaboration with Ionis on the FLAME discovery engine, following Flamingo’s Series A financing in 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement and discovery alliance will leverage Flamingo’s deep expertise in oncology and long non-coding RNAs (lncRNAs) in combination with Ionis’ expertise in RNA-targeted drug discovery and development to advance candidates against targets considered undruggable with traditional approaches. Flamingo’s pipeline will include three clinical-stage programs from Ionis, inhibitors of STAT-3, Androgen Receptor (AR) and IRF4, and one preclinical-stage program that targets MALAT1, a well-characterized lncRNA target. Flamingo will also advance its proprietary discovery engine, FLAME (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the dark matter of the human genome.

"We’re thrilled to strengthen our relationship with Ionis who has been at the forefront of RNA-targeted therapy for thirty years," said Michael Garrett, Chief Executive Officer of Flamingo. "We believe the combination of Ionis’ leadership in RNA and our cutting-edge lncRNA discovery engine will expand the opportunities for applying RNA-targeted approaches to oncology."

"We are pleased that Flamingo is leveraging their core strengths in developing novel cancer medicines to advance innovative Ionis-discovered oncology therapies where there is an unmet need," said Brett P. Monia, Ph.D., Ionis’ chief executive officer.

In connection with the alliance, Rob MacLeod, Ph.D., VP, Oncology Research & Development of Ionis, will serve as Chief Scientific Officer of Flamingo. Under the terms of the agreement, Ionis is eligible to receive milestone payments and royalties on future product sales of the STAT3, AR, IRF4 and MALAT1 programs. Flamingo retains full rights to its FLAME platform and all lncRNA programs outside of MALAT1.

Flamingo Therapeutics was founded by VIB, Ghent University, KU Leuven, the University of Michigan, Kurma Partners and PMV, based on pioneering work led by Professor Jean-Christophe Marine (VIB-KU Leuven), Professor Pieter Mestdagh (Ghent University) and Professor Arul Chinnaiyan (University of Michigan). These scientific teams broke new ground on non-coding RNA genes in cancer and were among the first to show a role for lncRNAs as disease drivers in oncology.

On September 9, 2021 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, reported that Dr. Joseph Tucker, MagicMed Industries’ ("MagicMed") Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and Virtual Gravitas Health Reimagined Investor Day (Press release, Enveric Biosciences, SEP 9, 2021, View Source [SID1234587582]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tucker’s H.C. Wainwright 23rd Annual Global Investment Conference presentation will be available on-demand beginning Monday, September 13th at 7:00 a.m. ET. To attend please register here.

Dr. Tucker is also scheduled to present on Thursday, September 16th at 10:00 a.m. PT / 1:00 p.m. ET at the Virtual Gravitas Health Reimagined Investor Day. To register for the event please use the following LINK.

On May 24, 2021, Enveric Biosciences announced the definitive agreement to acquire MagicMed Industries. Enveric and MagicMed will each hold a meeting of their respective stockholders. The Enveric annual meeting will be held virtually on September 14, 2021 at 10:00 a.m., Eastern Time, at www.virtualshareholdermeeting.com/ENVB2021.

For more information about each conference or to schedule a one-on-one meeting with MagicMed’s management team, please contact your appropriate H.C. Wainwright or Gravitas representative directly, or KCSA Strategic Communications at [email protected].

About the H.C. Wainwright 23rd Annual Global Investment Conference

H.C. Wainwright & Co. is hosting its 23rd Annual Global Investment Conference, which is being held as a virtual event from September 13-15, 2021. A record-setting number of participants are expected to view the 850+ company presentations scheduled as live feed or available as recorded for this year’s edition of the H.C. Wainwright Global Investment Conference.

The conference offers six sector tracks devoted to Healthcare & Biotech, Metals & Mining, Cryptocurrency, Blockchain & FinTech, CleanTech, Technology, Media & Telecommunications and Shipping & Maritime.

The daily format includes corporate presentations, investor one-on-one meetings, topical presentations by keynote speakers and virtual evening events to encourage informal interaction amongst conference participants. The annual conference is a "must see" event for institutional investors of all types, private equity firms, venture capitalists, industry executives and business development executives.

About the Gravitas Health Reimagined Investor Day
This year’s Gravitas Health Reimagined Investor Day will feature several leaders in the healthcare space and will be attended virtually by institutional and retail investors from North America and abroad. For additional details about the conference and Gravitas Securities Inc., please visit: www.gravitassecurities.com

On September 9, 2021 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported its financial outlook for full year 2021 (Press release, Quest Diagnostics, SEP 9, 2021, View Source [SID1234587568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since the company reported its financial performance for the second quarter of 2021 on July 22, 2021, COVID-19 molecular testing volumes were stronger than anticipated through the end of August and are expected to continue to be stronger than anticipated because of the surge of the Delta variant. The low end of the company’s outlook now assumes average COVID-19 volumes of at least 40,000 molecular tests per day for the second half of the year. Organic testing volumes in the company’s base business (excluding COVID-19 molecular and antibody testing and the impact of recent acquisitions) remain consistent with its previous outlook.

Updated Outlook for Full Year 2021

The company revised its full year 2021 outlook as follows:

The company is scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference today at 9:30 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. During the discussion, the company’s management plans to discuss the company’s vision, goals and two-point strategy to accelerate growth and drive operational excellence, as well as the company’s current perspective on the impact of the COVID-19 pandemic.

Management continues to believe that the COVID-19 pandemic’s impact on its future operating results, cash flows and/or financial condition will be primarily driven by a number of factors beyond the company’s knowledge and control, including: the pandemic’s severity and duration; healthcare insurer, government, and client payer reimbursement rates for COVID-19 molecular tests; the pandemic’s impact on the U.S. healthcare system and the U.S. economy; and the timing, scope and effectiveness of federal, state and local governmental responses to the pandemic including the impact of vaccination efforts.

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, certain financial impacts resulting from the COVID-19 pandemic, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, costs associated with donations, contributions and other financial support through Quest for Health Equity, the company’s initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, a gain on the sale of an ownership interest in a joint venture and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts; and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional table attached below includes a reconciliation of non-GAAP adjusted measures to GAAP measures.